Metabolon, Inc.

Partnership seeks to identify rheumatoid arthritis biomarkers to improve understanding of disease risk, progression, and treatment responses MORRISVILLE, N.C. and GLASGOW, Scotland, Aug. 28, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, and the Scottish Early Rheumatoid Arthritis (SERA) Study, today announced a partnership to identify circulating small molecules that may be used as biomarkers of rheumatoid arthritis disease risk, progression, and treatment response. By linking Metabolon's unique library of small molecules with SERA's well-characterized cohort, this partnership will combine metabolomic data with clinical and genomic information to better understand the molecular mechanisms of rheumatoid arthritis disease development and progression. As of 2019, there were approximately 18 million cases of rheumatoid arthritis globally. This condition predominantly affects women, who make up about 70% of those diagnosed. Additionally, over half of the individuals with this disease are aged 55 or older. Out of the total affected, around 13 million suffer from moderate to severe forms of rheumatoid arthritis, which indicates a potential need for rehabilitation. Rheumatoid arthritis is an autoimmune disorder that impacts various systems within the body, primarily targeting joints. For the study, the SERA inception cohort and biobank recruited 1073 patients from across Scotland, UK, with newly diagnosed RA or undifferentiated arthritis between March 2011 and April 2015. Clinical characteristics, including therapeutics and disease activity parameters, were recorded with a broad range of biobanked biological samples. "Our original ambition in establishing the SERA cohort was to facilitate a deeper understanding of the causes of rheumatoid arthritis and how affected individuals progress in their disease," said Iain McInnes, Vice Principal and Head of College, University of Glasgow. "This, in turn, helps us identify better patient treatments and make wiser treatment choices. Our new collaboration with Metabolon is an exciting step forward in the search for improved predictive therapies for patients." Genetic susceptibility is thought to account for approximately 60% of rheumatoid arthritis cases; however, an environmental trigger is hypothesized to lead to the development of rheumatoid arthritis. Metabolomics is the perfect complement to the SERA study since metabolomics sits at the intersection of genetic and environmental cues. These combined multiomic datasets will facilitate a deeper understanding of the pathology of rheumatoid arthritis, hopefully resulting in improved diagnostic and treatment options. "Rheumatoid arthritis is an extremely diverse disorder characterized by a wide range of disease severity, phenotypes, and treatment responses. Currently, there is no cure for rheumatoid arthritis, but there are drugs available that can slow disease progression. Treatments are often tailored through trial and error because there's no standard way to group patients for specific treatments," said Karl Bradshaw, Chief Business Officer at Metabolon. "By integrating metabolomics into SERA's robust cohort, we hope to identify data patterns and stratify patients to develop personalized treatment plans." To learn more about how large disease-focused cohorts are integrating metabolomics into their multiomic research, please visit: About Metabolon Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other 'omics' technologies. With more than 20 years, 10,000+ projects, 3,000+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Metabolon's Global Discovery Panel is powered by the world's largest proprietary metabolomics reference library. Metabolon's industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, that support customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit and follow us on LinkedIn and Twitter. About Metabolomics Metabolomics, the large-scale study of all small molecules in a biological system, is the only 'omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic and external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug's mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy. About the Scottish Early Rheumatoid Arthritis (SERA) Study The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate the discovery of phenotypic and prognostic biomarkers. SERA is a consortium made up of the Universities of Aberdeen, Dundee, Edinburgh and Glasgow, the NHS Scotland, Pfizer, and the Scottish Government Chief Scientist Office. SOURCE Metabolon, Inc.

MORRISVILLE, N.C., July 16, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced the expansion of its metabolite library to include 70 pesticides, strengthening the company's ability to provide comprehensive environmental exposure insights via metabolomics analysis. Nearly two billion people are involved in agriculture globally, many of whom are exposed to pesticides on a regular basis. More than one billion pounds of pesticides are applied annually in the United States, while global usage is around 5.6 billion pounds per year. However, there is a limited understanding of how repeated pesticide exposure impacts human health and reproductivity. Unlike other multiomics solutions, metabolomics is uniquely suited to offer valuable insights for researchers seeking to understand the exposome – metabolomics not only reveals which pesticides we've been exposed to but can also help assess the degree to which these pesticides impact our health. "Employing metabolomics to measure the exposome results in a better understanding of the collective health effects of environmental chemicals, including pesticides," said Ro Hastie, President & CEO at Metabolon. "Our latest library expansion underscores our commitment to advancing metabolomics research and providing our customers with unique insights into the exposome." With this library expansion, Metabolon extends its coverage of exposome-related molecules that can be identified with Level 1 certainty. These additions meaningfully bolster Metabolon's library, further enabling a unique and holistic view of the interaction between people and the chemicals to which they are exposed, encompassing industrial, pharmaceutical, food, bacterial, and fungal origins. For more information on Metabolon's industry-leading library, please visit . About Metabolon Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other 'omics' technologies. With more than 20 years, 10,000+ projects, 3,000+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Metabolon's Global Discovery Panel is powered by the world's largest proprietary metabolomics reference library. Metabolon's industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, that support customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit and follow us on LinkedIn and Twitter. About Metabolomics Metabolomics, the large-scale study of all small molecules in a biological system, is the only 'omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic and external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug's mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy. SOURCE Metabolon, Inc.

MORRISVILLE, N.C., June 25, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, is proud to announce the receipt of a prestigious grant from the National Institutes of Health (NIH) to develop an innovative product aimed at better monitoring and predicting the conversion of preclinical asymptomatic type 1 diabetes (T1D) to clinical symptomatic, insulin-dependent type 1 diabetes. Over 3 million people in the United States live with T1D. Today, the biomarkers that predict the progression of preclinical T1D to clinical T1D lack specificity and granularity. Despite advances in medical research, no single FDA-approved test currently can monitor T1D progression beyond simple disease staging. Metabolon's new initiative addresses this unmet need by identifying metabolite biomarkers to improve prediction and enable a more detailed understanding of disease progression when evaluated alongside current clinical indicators. "Metabolon has a rich history of pioneering advancements in metabolomics. We are dedicated to empowering pharmaceutical and biotechnology companies, as well as academic and government institutions, with comprehensive metabolic insights to drive better health outcomes," said Ro Hastie, CEO of Metabolon. "With this NIH grant, Metabolon is poised to extend its expertise in T1D, aiming to enhance predictive capabilities and improve the lives of millions affected by this condition." If successful, Metabolon's research will enhance the specificity and granularity of T1D progression prediction and pave the way for more precise and personalized treatment strategies. By integrating new metabolite biomarkers with existing clinical indicators, Metabolon's efforts will significantly contribute to diabetes research and patient care. For more information about Metabolon's projects and services, please visit . About Metabolon Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other 'omics' technologies. With more than 20 years, 10,000+ projects, 3,000+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Metabolon's Global Discovery Panel is powered by the world's largest proprietary metabolomics reference library. Metabolon's industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, that support customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit and follow us on LinkedIn and Twitter. About Metabolomics Metabolomics, the large-scale study of all small molecules in a biological system, is the only 'omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic and external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug's mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy. Logo -